Navigation Links
Profil Institute and Mercodia Announce Partnership Offering Insulin and Metabolism ELISA Assays to Enhance Diabetes and Obesity Clinical Trials
Date:4/10/2013

SAN DIEGO and UPPSALA, Sweden, April 10, 2013 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a clinical research institute optimizing early phase diabetes, obesity and cardiometabolic drug development, and Mercodia AB, an industry-leading developer of immunoassays for metabolic clinical and research applications, jointly announced today a strategic alliance to include Mercodia's enzyme-linked immnosorbent assays (ELISA) as a component of Profil Institute's early phase clinical services. 

Both Profil Institute and Mercodia are widely recognized for their expertise in diabetes, obesity and cardiometabolic research.  Profil Institute is a center of excellence for early phase metabolic clinical research and is renowned for its expertise in proof of mechanism methods, including first-in-patient and automated glucose clamp studies, and its large patient recruitment database.  Mercodia is globally recognized for its robust ELISA assay development for metabolic clinical research and to study the pharmacokinetics of insulin and metabolic peptides.  Mercodia's assays will now be offered to Profil Institute's clients as a component of the clinical trial process. 

"With the addition of Mercodia's robust ELISA assays, we further enhance our wide scope of clinical research services, generating unprecedented investigative standards for early phase diabetes and obesity drug development," said Dr. Marcus Hompesch , Profil Institute CEO. "Our scientific understanding of diabetes and of the pharmacokinetic and pharmacodynamic effects of insulin, as well as our expertise working with all diabetes drug classes, enables us to provide highly conclusive data so that our clients can make the best decisions, as early as possible, about the further development of their drug candidates."

"We are very pleased to partner with Profil Institute and therefore combine our disease area expertise for a powerful outcome in the precision of clinical research data," said Mona Österberg, CEO of Mercodia AB.  "Together we will deliver greater scientific insight to Profil Institute's customers enhancing their overall metabolic drug development program at the earliest stage of clinical research in humans."

About Mercodia AB
Mercodia AB is a Swedish biotech company focusing on the development of highly reproducible and specific ELISA assays within the field of metabolic disorders.  Mercodia is a world-leading supplier to all major international markets and provides a professional scientific support system to develop novel applications for existing products and unique diagnostics for emerging markets.  The facilities include a GLP-compliant laboratory and a customized assay development core managed by our extensive quality system and ISO 13485 for manufacturing medical devices.  For more information visit www.mercodia.com.

About Profil® Institute for Clinical Research, Inc.
Profil Institute is internationally renowned as a Center of Excellence for early phase clinical research of drugs and devices for diabetes, obesity and cardiometabolic diseases. The company's scientific expertise, advanced metabolic clinical research methodologies, and automated glucose clamp technology enable Profil Institute to execute studies of far more complexity and have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug studies. Profil Institute has been involved with every clinically promising drug class in diabetes and in more than 175 clinical studies since the company's inception in 2004. For more information visit www.profilinstitute.com


'/>"/>
SOURCE Profil Institute for Clinical Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
2. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
3. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
4. Abaxis Announces the Launch of Kidney Profile Plus Panel
5. NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study
6. Group Florence Nightingale Increases Radiosurgery Profile with Acquisition of Turkeys First Leksell Gamma Knife Perfexion System
7. Varian Medical Systems Selected by Leading Russian Development Foundations to Take Part in High-Profile Supplier Event
8. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at RnRMarketResearch.com
9. High Profile HealthCare Companies: Leading Pharma Company Secures New Patents
10. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
11. Fortune Magazine Profiles ArcView Group, Co-founded by Steve DeAngelo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , February 20, 2017 According to a new ... Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, ... by MarketsandMarkets, The market is projected to reach USD 52.37 Billion by ... during the forecast period. Continue Reading ... ...
(Date:2/20/2017)...   Alberty   Drugs , a ... has announced a significant shift in focus by ... to servicing local Veteran Affairs Centers (VA) and other ... increased need to secure cost effective treatments for their ... for their goods & services. "The opportunity ...
(Date:2/20/2017)... , February 20, 2017 Acute, Chronic and ... expected to grow at a CAGR of 7% from 2016-2021 and CAGR ... CAGR of 6% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business opportunities ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... ... Smiles by Seese is a comprehensive family dental practice located ... practice as a skilled and highly credentialed dentist who is qualified to perform a ... all ages with excellence in general, restorative, and cosmetic dentistry . Their services ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... on foundational and sustainable systems change designed to further positively impact the health ... Board of Trustees has long considered it our duty to seriously consider releasing ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Carol Francis' goals for each and every seminar, session and class she ... demonstrate five different brainwave tools which help energize creativity, focus mental functions, enhance ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum Awards ... healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, highlighting ...
Breaking Medicine News(10 mins):